Amivantamab, the first epidermal growth factor receptor and mesenchymal–epithelial transition factor inhibitor, associated with penile and inguinal ulcers and paronychia

Amivantamab, the first epidermal growth factor receptor and mesenchymal–epithelial transition factor inhibitor, associated with penile and inguinal ulcers and paronychia

Bibliographic Details
Main Authors: Karina J. Cancel-Artau, MD, Angélica C. Marrero-Pérez, MD, Eduardo A. Michelén-Gómez, MD, Xavier Sánchez-Flores, MD
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:JAAD Case Reports
Subjects:
amivantamab
endothelial growth factor receptor inhibitor
ulcer
Online Access:http://www.sciencedirect.com/science/article/pii/S2352512624000250

Similar Items

Similar Items